CollPlant Biotechnologies
CLGN
2 hedge funds and large institutions have $122K invested in CollPlant Biotechnologies in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$76.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$54.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $72K | +$76.5K | +13,885 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $50K | +$54.2K | +9,831 | New |
|
CLGN Hedge Fund Activity: Q3 2018 in Review
2 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2018, worth a combined $122K.
Buyers outnumbered sellers: 2 funds opened new CLGN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $76.5K.
- 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $122K of CollPlant Biotechnologies stock for Q3 2018.
- 2 funds opened new CollPlant Biotechnologies positions in Q3 2018 and 0 closed out, a net change of +2 holders.
- The largest CollPlant Biotechnologies buyer in Q3 2018 was Citadel Advisors, an estimated $76.5K added.
Based on aggregated 13F filings for Q3 2018.